ABOUT US

 

IsletOne Therapeutics develops and commercializes innovative cell therapy technology

The company is capitalizing on the fertile translational environment at the Karolinska Institute and the Karolinska University Hospital, with asset-centric operations focused on developing and protecting its innovative science and technology platform. IsletOne has secured early groundbreaking intellectual property (IP) protection for a pipeline comprising R&D programs and applications in a wide range of inflammatory and immune-mediated disorders. The company harnesses the regenerative and immuno-modulatory capabilities of mesenchymal stromal cells (MSCs) in areas with significant unmet medical need, with a focus on cardiology, transplantation, and autoimmunity/inflammation.

 

IsletOne’s management

IsletOne's management makes up a seasoned and start-up savvy team that contributes with complementary expertise in pre-clinical and clinical R&D, corporate strategy, IP management and development, clinical development, and financing and fundraising.

Copyright © All Rights Reserved

ADRESS

IsletOne AB
Hälsovägen 7,  SE-14157, Huddinge, Sweden

CONTACT US